www.antimicrobe.org

[Start Page] [Microbes] [Antimicrobial Agents] [HIV Clinical Manual] [Feedback] [Logout]

Hepatitis B Virus

 

Read the Chapter

Sliding Table of Contents on the left of the screen

 

Tables and Figures

Table 1: Hepatitis B Proteins

Table 2: Guidelines for Hepatocellular Carcinoma Surveillance in HBsAg Carriers

Table 3: Phases of Chronic Hepatitis B Infection

Table 4:  Guidelines for Initiation of Antiviral Therapy in Chronic Hepatitis B

Table 5: Serologic Assessment of Hepatitis B Infection

Table 6: Antiviral Agents Approved for Treatment of Chronic Hepatitis B Infection

Table 7: Efficacy of Antiviral Therapy for HBeAg-Positive Chronic Hepatitis B

Table 8: Efficacy of Antiviral Therapy for HBeAg-Negative Chronic Hepatitis B

Table 9:  Management of Drug Resistance Associated with Hepatitis B Therapy

Table 10: Hepatitis B Vaccines

Table 11: Candidates for Hepatitis B Vaccination

Figure 1. Hepatitis B Life Cycle

Figure 2: Hepatitis B Genome

Figure 3: Risk of Hepatocellular Carcinoma Based on Hepatitis B Viral Load

Figure 4:  Efficacy of Antiviral Therapy for Hepatitis B

Figure 5:  Antiviral Drug Resistance Associated with Nucleoside and Nucleotide Analogues

 

Vignettes

Review Article: Lok ASF, McMahon BJ. Chronic Hepatitis B: Update 2009.  AASLD Practice Guidelines. Hepatology 2009:50;1-36.

Review Article:  Hoffman, C., Thio, C. Clinical Implications of HIV and Hepatitis B Co-infection in Asia and Africa. The LANCET Infectious Diseases 2007; Vol.7, Issue 6, 402-409.

Review Article:  Sorrell MF, et al.  National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis B.  Ann Intern Med 2009;150(2):104-10.

Review Article: Keeffe EB, et al.  A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update. Clin Gastroenterol Hepatol. 2008;6:1315-1341.

FDA Approves Tenofovir for Hepatitis B. 2008.

Marcellin P, et al.  Tenofovir disoproxil fumarate versus aadefovir dipivoxil for chronic hepatitis B.  NEJM 2008;359:2442-2455.

FDA: FDA Approves First Nucleic Acid Test to Screen for Additional Types of HIV In Donated Blood and Tissues. December, 2008.

Hoa PT, Huy NT, et al. Randomized Controlled Study Investigating Viral Suppression and Serological Response Following Pre-S1/Pre-S2/S Vaccine Therapy Combined with Lamivudine Treatment in HBeAg-Positive Patients with Chronic Hepatitis B. Antimicrob Agents Chemother. 2009 Dec;53:5134-40.

Thompson ND, et al. Nonhospital Health Care-associated Hepatitis B and C Virus Transmission: United States, 1998-2008. Ann Intern Med. 2009. Jan 6;150(1):33-9.
Woo G, et al. Tenofovir and Entecavir are the Most Effective Antiviral Agents for Chronic Hepatitis B: a Systematic Review and Bayesian Meta-Analyses. Gastroenterology. 2010 Oct;139:1218-29.

Fung J et al. Entecavir Monotherapy is Effective in Suppressing Hepatitis B Virus After Liver Transplantation. Gastroenterology. 2011 Jul: [Epub ahead of print].

 

Author

Stevan B. Gonazlez, M.D., M.S.

Second Edition (2002): David Durantel, Ph.D., Béatrice Seignères, Ph.D., Fabien Zoulim, M.D., Ph.D.,

Stephanie Villet, Ph.D., Daviid Durantel, Ph.D., Fabien Zoulim, M.D., Ph.D.

First Edition (1998): Mang M. Ma, Graham A. Tipples, Karl P. Fischer, and David L. J. Tyrrell

 

www.antimicrobe.org

[Start Page] [Microbes] [Antimicrobial Agents] [HIV Clinical Manual] [Feedback] [Logout]